Circulating α-klotho levels in CKD and relationship to progression

Area of Science:

• Nephrology
• Biomarkers
• Chronic Kidney Disease

Background:

• α-Klotho demonstrates protective effects against kidney injury in experimental models.
• Renal expression of α-Klotho is often reduced in kidney disease.
• Circulating α-Klotho levels and their association with human CKD progression remain unclear.

Purpose of the Study:

• To investigate the relationship between circulating α-Klotho levels and the progression of chronic kidney disease (CKD).
• To determine if α-Klotho serves as a predictive biomarker for adverse outcomes in CKD patients.

Main Methods:

• Post hoc analysis of a prospective cohort study involving 243 participants with CKD.
• Measurement of baseline serum α-Klotho and FGF-23 using enzyme-linked immunosorbent assay.
• Cox regression analysis to assess the association between α-Klotho and composite outcomes (doubling of creatinine, ESRD, or death).

Main Results:

• Lower serum α-Klotho levels correlated with more severe CKD stages.
• Baseline α-Klotho independently predicted adverse kidney disease outcomes, including end-stage renal disease (ESRD) or death.
• Patients with lower α-Klotho levels had a significantly higher risk of reaching the primary composite outcome.

Conclusions:

• Low circulating α-Klotho levels are associated with adverse outcomes in patients with chronic kidney disease.
• α-Klotho may represent a novel biomarker for predicting CKD progression.
• Further validation in larger prospective studies is warranted.